Guidance

Smallpox vaccine PGD template

PGD template for administering smallpox vaccine in response to mpox (monkeypox).

Applies to England

Documents

Smallpox patient group direction (PGD) template

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of the smallpox vaccine, modified vaccinia virus Ankara - Bavarian Nordic (MVA-BN), to individuals identified for immunisation in response to mpox.

The smallpox PGD version 3.00 is valid from 15 September 2023 to 15 September 2024.

For information:

  • at present, there are no stocks of the UK licensed MVA-BN vaccine Imvanex® available
  • Medicines and Healthcare products Regulatory Agency (MHRA) granted batch-specific variation for batch number FDP00072 of the US licensed vaccine Jynneos® is the only batch allowed to be used under this PGD

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy or procedures to access authorised PGD documents.

This PGD template should used with reference to current national recommendation on mpox vaccination, the Green Book and the Direct Healthcare Professional Communication letter from Bavarian Nordic the differences between Imvanex® brand (licensed in UK) and Jynneos® brand (licensed in US) of live modified vaccinia virus Ankara.

Published 5 August 2022
Last updated 5 September 2023 + show all updates
  1. Added version 3 - see page 2 for change history.

  2. Added version 2.00 – details of changes on page 2 and updated batch information.

  3. Corrected review date.

  4. First published.